Parkinson's disease (PD) is a neurodegene Parkinson's disease (PD) is a neurodegenerative disorder occurring after an extensive loss of midbrain dopamine (DA) neurons that regulate normal body movements. The small protein, ?D-synuclein (a-Syn), is implicated in PD by its abundance in Lewy bodies and by geo 14-3-3 chaperones to regulate the activity of key enzymes. One such enzyme is tyrosine hydroxylase (TH), which is rate limiting for DA synthesis, and a protein that can be activated by 14-3-3 binding. Using in vitro models our laboratory discovered that a-Syn binds to and inhibits TH. We also found that a-Syn also inhibits DA synthesis by reducing the activity of the second enzyme in the DA biosynthetic pathway, aromatic amino acid decarboxylase (AADC). Short term regulation of TH and AADC activity is mediated by changes in protein phosphorylation/dephosphorylation. TH is known to be dephosphorylated by the protein phosphatase PP2A. Recent findings from our laboratory reveal that a-Syn binds to and activates this very phosphatase. Cumulatively, the data lead us to hypothesize that soluble a-Syn contributes to normal DA levels by inhibiting TH and AADC, but as a-Syn aggregates DA is overproduced, initiating a feed-forward cascade of reactive species that compromises nigrostriatal dopaminergic neuronal viability. The goal of this proposal is to extend and confirm our in vitro findings in vivo using mouse models to measure the impact of a-Syn on PP2A and TH with regard to DA synthesis. To achieve this, we will use multiple transgenic lines of a-Syn mice and assays utilizing recombinant proteins. In vivo we will modulate a- Syn levels by lentiviral transduction and then measure the effects of soluble and aggregated a-Syn on TH and PP2A by immunoblots, enzyme assays, immunohistochemistry, and confocal microscopy. In vitro we will use recombinant proteins to measure the impact of aggregated a-Syn on TH and PP2A activity as measured using well characterized enzymatic assays as we test the following hypotheses: 1) that a-Syn inhibits DA synthesis by effects on TH and PP2A in vivo, and 2) that soluble a-Syn stimulates PP2A and inhibits TH activity, while aggregated a-Syn is unable to do so, as measured in vitro and in vivo. We are uniquely positioned to elucidate the biological and translational relevance of a-Syn as a regulator of DA homeostasis, with the potential to identify novel preventative or restorative PD therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
7R01NS042094-08
Application #
8325230
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Sutherland, Margaret L
Project Start
2001-07-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2010
Total Cost
$286,121
Indirect Cost
Name
Texas Tech University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
609980727
City
Lubbock
State
TX
Country
United States
Zip Code
79430
Enoru, Julius O; Yang, Barbara; Krishnamachari, Sesha et al. (2016) Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy. PLoS One 11:e0162162
Vidal-Martínez, Guadalupe; Vargas-Medrano, Javier; Gil-Tommee, Carolina et al. (2016) FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. J Biol Chem 291:20811-21
Vargas-Medrano, Javier; Krishnamachari, Sesha; Villanueva, Ernesto et al. (2014) Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells. ACS Med Chem Lett 5:782-6
Farrell, Kaitlin F; Krishnamachari, Sesha; Villanueva, Ernesto et al. (2014) Non-motor parkinsonian pathology in aging A53T ?-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function. J Neurochem 128:536-46
Wu, J; Lou, H; Alerte, T N M et al. (2012) Lewy-like aggregation of ?-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 207:288-97
Geng, Xuehui; Lou, Haiyan; Wang, Jian et al. (2011) ?-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 300:E276-86
Lou, Haiyan; Montoya, Susana E; Alerte, Tshianda N M et al. (2010) Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 285:17648-61
Wang, Jian; Lou, Haiyan; Pedersen, Courtney J et al. (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 284:14011-9
Alerte, Tshianda N M; Akinfolarin, Akinwande A; Friedrich, Emily E et al. (2008) Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci Lett 435:24-9
Tehranian, Roya; Montoya, Susana E; Van Laar, Amber D et al. (2006) Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem 99:1188-96

Showing the most recent 10 out of 12 publications